Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients

International Journal of Colorectal Disease

Volumn 15, Issue 4, 2000, Pages 197-205

  Marten, A ^a   Ziske, C ^a   Schottker, B ^a   Renoth, S ^a   Weineck, S ^a   Buttgereit, P ^a   Schakowski, F ^a   Klingmuller, D ^a   Scheffold, C ^a,b   von Rucker, A ^a   Sauerbruch, T ^a   Schmidt Wolf, I G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ca 19 9; Dendritic Cells; Immunological effector cells; Immunotherapy

Indexed keywords

CA 19-9 ANTIGEN; MYOGLOBIN; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CARCINOMA CELL; CELL ACTIVATION; CELL CULTURE; CELL STIMULATION; CELL SURFACE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; HEAT SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOTHERAPY; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; SERUM; SOLID TUMOR; TARGET CELL; TUMOR RESISTANCE;

CA-19-9 ANTIGEN; CELLS, CULTURED; COCULTURE TECHNIQUES; COLORECTAL NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033835920     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840000243     Document Type: Article

References (27)

1. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms
2. Dendritic cells and the control of immunity
3. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9-protein
4. Propagation of large numbers of T cells with natural killer cell markers
5. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
6. A rapid and simple procedure for dissociation of tumor tissue from the human colon
7. Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes
8. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes
9. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
10. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells
11. Cellular immunotherapy and autologous transplantation for hematologic malignancy
12. Lineage relationships and differentiation of natural killer (NK) T cells: Intrathymic selection and interleukin (IL)-4 production in the absence of NKR-P1 and Ly49 molecules
13. IL-4-producing NK T cells are biased towards IFN-gamma production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells
14. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
15. Dendritic cells: Unique leukocyte populations which control the primary immune response
16. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
17. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
18. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
19. Dendritic cells as adjuvants for immune-mediated resistance to tumors
20. Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation
21. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
22. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
23. Vaccination of patients with multiple myeloma using idiotype pulsed autologous dendritic cells derived from highly purified CD34 progenitor cells
24. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
25. Dendritic cells for autologous tumor vaccination in chronic myeloid leukemia
26. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: Implications for studies on antigen-presenting cell function and immunotherapy
27. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire